We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global Hospital Acquired Infections Testing Kits Market to Reach USD 1.8 Billion by 2026

By LabMedica International staff writers
Posted on 08 Apr 2022

The global hospital acquired infections testing kits market is expected to grow at a CAGR of 12.7% from USD 1.12 billion in 2021 to USD 1.27 billion in 2022 and is projected to grow further at a CAGR of 8.8% to USD 1.78 billion in 2026, driven by increased incidence of chronic diseases. The rates of hospital acquired infection are higher among patients with increased susceptibility due to old age and underlying chronic diseases, such as COVID-19.

These are the latest findings of The Business Research Company (London, UK), a market intelligence firm.


Image: Global HAI testing kits market will be driven by increased chronic diseases (Photo courtesy of Unsplash)
Image: Global HAI testing kits market will be driven by increased chronic diseases (Photo courtesy of Unsplash)

The unprecedented coronavirus outbreak has caused a surge in the demand for hospital acquired infections testing kits, due to the rise in hospital acquired infections during the pandemic. The pandemic has raised enormous concerns over the quality of care in hospitals, due to the rising number of patients during COVID-19 and the change in staffing numbers. Multiple hospitals have experienced an increase in staffing levels, with traveling nurses reporting that these nurses were unfamiliar with hospital infection control processes. Such circumstances have made it difficult for hospitals to maintain patient safety and quality of care.

Increasing healthcare expenditure is predicted to drive a surge in the demand for hospital acquired infections testing kits. The growth in healthcare expenditure is aiding governments and organizations to spend more on prescription drugs, hospitals, and physical & clinical services, thereby driving the hospital acquired infections testing kits market. Consequently, the rise in healthcare spending will continue to drive an increase in the demand for hospital acquired infections testing kits in the near future.

Geographically, North America held the largest share of 36.2% of the global hospital acquired infections testing kits market in 2021, followed by the Asia-Pacific and other regions. Going forward, South America, Africa and the Middle East will be the world’s fastest-growing markets for hospital acquired infections testing kits with a CAGR of 9.3%, 8.8% and 8.8%, respectively, followed by the Asia Pacific and Western Europe.

Related Links:
The Business Research Company 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Latest Industry News

Siemens to Close Fast Track Diagnostics Business

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems